Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) is investing money in manufacturing facility to speed up the cell therapy clinical trials for use in curing cancer, just like rivals Juno Therapeutics and Kite Pharma. A 27,000 square feet space has been leased to build the CAR-T Therapy cells that will help cancer patients to develop a strong immunity. According to a company release, the new manufacturing facility will be situation at the Houston campus of Bellicum, which is never the Texas Medical Center.
The move is aimed at giving more focus to the development of the cell therapies at one place without hiring anyone else to do the work. Even Novartis has built separate facilities for caring the clinical trials on the same and every pharmaceutical company is trying to develop therapies that can work better than the rest.
Manufacturing Facility Benefit
CEO of Bellicum Pharmaceuticals Inc (NASDAQ:BLCM), Tom Farrell said in an official statement that an in-house manufacturing destination was essential to successfully build upon the process, analyze the development proficiency and have a better cell therapy mechanism. The upcoming facility would be providing the drug for the clinical trials of BPX-501 and support development of TCR and CAR-T cell therapies.
BPX-501 is an effective therapy for the cancer patients undergoing stem cell transplants is Bellicum’s most progressive positive feature, and a similar skill has been applied to oncology. To cure cancer, Bellicum is working on a series of cancer therapies like BPX-401 for fighting hematological cancer cells, BPX-601 to target solid tumors, and BPX-701 for the skin cancer treatment.
Bellicum Safety Switch
The cell therapies of Bellicum come with a unique safety switch to ward off unnecessary reactions from transplants, including the cytokine release syndrome and this will help them tackle their rivals. This observation has also been noted by researchers and they feel that all pharmaceutical companies that are developing CAR T cell therapies need to include a switch to safeguard the healthy cells in the body. This is needed to be done specifically for therapies that lead to side-effects like deadly fevers and inflammation in the body.
These cancer therapies can become a major revenue fetcher for the companies if approved by the authorities.
